Hematological Neoplasms
**Treatment for Multiple Myeloma: China’s BCMA×CD3 Bispecific Antibody Proposed for Breakthrough Therapy Designation** #MultipleMyeloma #BCMAxCD3 #BispecificAntibody #Immunotherapy #GR1803 #NMPA #RRMM Recently, GR1803, an injectable solution developed by Genrix Bio, has been proposed for the “Breakthrough Therapy Designation” by the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA). This innovative drug targets Read More
Yescarta, also known as axicabtagene ciloleucel, is a revolutionary chimeric antigen receptor T-cell (CAR-T) therapy that has been hailed as a significant breakthrough in the treatment of certain types of lymphoma.
CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL) #MantleCellLymphoma #MCL #Lymphoma #RRMCL #RelmaCel #CART #Non-HodgkinLymphoma #NHL In the global cancer treatment landscape, the advancements in CAR-T cell therapy are remarkable, particularly in the treatment of relapsed and refractory Mantle Cell Lymphoma (MCL). China’s CAR-T therapy, Relma-cel, Read More
**China’s CAR-T Therapy Approved for New Indication: Bringing New Hope to Relapsed Mantle Cell Lymphoma Patients** The approval of Relmacabtagene Autoleucel brings renewed hope for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL). MCL is a rare and aggressive subtype of non-Hodgkin lymphoma (NHL). Despite advancements in treatment options over recent years, Read More
China’s Fully Human BCMA CAR-T Therapy: Bringing New Hope for High-Risk Relapsed/Refractory Multiple Myeloma Multiple Myeloma (MM) is a complex and aggressive cancer originating from plasma cells, posing significant treatment challenges due to its resistance to therapy. For patients with high-risk MM, especially those who experience relapse after multiple lines of treatment, finding an effective Read More